Great post Diver, I'd like to see the moderators sticky this post.
When it comes to timelines, I've yet to see a biotech I was involved in meet their timelines when they gave precise dates, and in most cases they're no more specific than our management where they "HOPE" to have this or that done at some time. I've yet to see a CEO or senior manager that didn't think that things could be done faster than is possible. Every task looks easy when others are doing it, when you have to do it yourself you often learn it's not as easy as you thought.
I'm not suggesting our management is perfect, they're far from it, but they're getting the job done. Some mngt. may have done it better, but others would have been belly up by now, we're actually in a very strong position, though we certainly could use some additional funds.
I know people don't like dilution, I don't mind it if it's done properly. I believe once the news is out and we have the Annual Meeting our share price will be at least a few dollars, perhaps over $5. At that point bringing in say $100 million with dilutive funding isn't so terrible and would position the company beautifully for gaining the approval from the 4 regulators and expanding the trials to take DCVax-L into additional indications and getting DCVax-Direct into pivotal trials in several indications. I believe the likelihood of a partnership or buyout at any time after the share price is above $5 and could warrant an offering that's in double digits. If it's a partnership I believe it will bring all the funding that will be needed in the foreseeable future. If we're bought out, that's it, the only choice we may have is taking cash, or stock in the company purchasing us. I much prefer a partnership.
Gary
Market Data 
Markets 
AI
